Nikhil C. Munshi, MD
Adjunct Associate Professor, Medicine
Biography
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Other Positions
- VA Boston Healthcare System
Education
- Maharaja Sayajirao University, MD
- Maharaja Sayajirao University, MBBS
Publications
- Published on 9/26/2023
Little JS, Tandon M, Hong JS, Nadeem O, Sperling AS, Raje N, Munshi N, Frigault M, Barmettler S, Hammond SP. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv. 2023 Sep 26; 7(18):5485-5495. PMID: 37486599.
Read at: PubMed - Published on 9/1/2023
Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martin N, Anderson LD, Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser SM. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel. Blood Cancer Discov. 2023 Sep 01; 4(5):365-373. PMID: 37486974.
Read at: PubMed - Published on 8/30/2023
Fillmore NR, La J, Wu JT, Corrigan JK, Branch-Elliman W, Monach P, Brophy MT, Do NV, Munshi NC. Even after SARS-CoV-2 Booster There is Increased COVID-19 Breakthrough Infection in Patients with Plasma Cell Disorders. Blood Adv. 2023 Aug 30. PMID: 37647600.
Read at: PubMed - Published on 8/28/2023
Paiva B, Zherniakova A, Nuñez-Córdoba JM, Rodriguez-Otero P, Shi Q, Munshi NC, Durie B, San-Miguel J. Impact of treatment effect on MRD and PFS: an aggregate analysis from randomized clinical trials in multiple myeloma. Blood Adv. 2023 Aug 28. PMID: 37639322.
Read at: PubMed - Published on 8/24/2023
Richardson PG, Durie BG, Rosiñol L, Mateos MV, Dispenzieri A, Moreau P, Kumar S, Raje N, Munshi N, Laubach JP, O'Gorman P, O'Donnell E, Voorhees P, Facon T, Bladé J, Lonial S, Perrot A, Anderson KC. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica. 2023 Aug 24. PMID: 37608773.
Read at: PubMed - Published on 8/23/2023
Samur MK, Aktas Samur A, Corre J, Lannes R, Shah P, Anderson KC, Avet-Loiseau H, Munshi NC. Monoallelic Deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023 Aug 23. PMID: 37611163.
Read at: PubMed - Published on 8/17/2023
Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023 Sep; 29(9):2286-2294. PMID: 37592106.
Read at: PubMed - Published on 8/15/2023
DuMontier C, La J, Bihn J, Corrigan J, Yildirim C, Dharne M, Hassan H, Yellapragada SV, Abel GA, Gaziano JMM, Do NV, Brophy MT, Kim DH, Munshi NC, Fillmore NR, Driver JA. More intensive therapy as more effective treatment for frail patients with multiple myeloma. Blood Adv. 2023 Aug 15. PMID: 37582048.
Read at: PubMed - Published on 7/27/2023
Samur MK, Szalat R, Munshi NC. Single-cell profiling in multiple myeloma: insights, problems, and promises. Blood. 2023 Jul 27; 142(4):313-324. PMID: 37196627.
Read at: PubMed - Published on 7/18/2023
Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023 Jul 18. PMID: 37463058.
Read at: PubMed
View 561 more publications: View full profile at BUMC